GSK and Vir turn to US for dis­tri­b­u­tion as Covid-19 mAb treat­ment nears block­buster sta­tus

Ever since for­mer Pres­i­dent Trump re­ceived an in­fu­sion of Re­gen­eron’s mon­o­clon­al an­ti­body, all three of the now-au­tho­rized Covid-19 mAb treat­ments have been in the spot­light.

The on­ly one fly­ing some­what un­der the radar is al­so the one to most re­cent­ly re­ceive an emer­gency au­tho­riza­tion, which came last May for Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s mAb sotro­vimab. But that third-to-mar­ket sta­tus hasn’t stopped the com­pa­nies from quick­ly sell­ing about $1 bil­lion worth of dos­es in the first six months and re­cent­ly sign­ing a $280 mil­lion US gov­ern­ment con­tract.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER